Patent Claims

1. Compounds of the formula I

5		$ \begin{array}{c c} R^4 & R^2 \\ \hline & R^5 & R^3 \end{array} $
10	in which	
	X	denotes C or N,
	В	denotes N, CH or C-CN,
	R^1	denotes H, A, OH, NH ₂ , -(CH ₂) _m -Ar or -(CH ₂) _m -Het ² ,
	R^2	if X = N is absent or
15		if $X = C$ denotes H, A, Hal, CN, -(CH ₂) _p -Ar,
		- $(CH_2)_p$ - $COOH$, - $(CH_2)_p$ - $COOA$, - $(CH_2)_p$ - Het^3 ,
		-(CH ₂) _p -NH ₂ , SO ₂ A, CHO or COA,
	R^3	denotes H, A, -S-A, - $(CH_2)_p$ -Ar, - $(CH_2)_p$ -Het, NH- $(CH_2)_p$ -
20		Ar, NH-(CH ₂) _p -Het, NH ₂ , NHA, NA ₂ , NH-alkylene-NH ₂ ,
		NH-alkylene-NHA, NH-alkylene-NA ₂ or NA-alkylene-NA ₂ ,
	R⁴	denotes -(CH ₂) _s -(Ar ¹) _n -Y-R ⁶ ,
	R⁵	denotes H or CH ₃ ,
25	R⁴ and R⁵	together also denote $Het^4 - N < CH_2 - CH$
	R^6	denotes Het^4 , $-(\operatorname{CH}_2)_r$ - NH_2 , $-(\operatorname{CH}_2)_r$ - NHA or $-(\operatorname{CH}_2)_r$ - NA_2 ,
	Υ	denotes O, S, $(CH_2)_q$ or NH,
30	Ar	denotes phenyl, naphthyl or biphenyl, each of which is
		unsubstituted or mono-, di- or trisubstituted by Hal, A,
		OH, OA, NH ₂ , NO ₂ , CN, COOH, COOA, CONH ₂ ,
		NHCOA, NHCONH ₂ , NHSO ₂ A, CHO, COA, SO ₂ NH ₂ ,
35		SO ₂ A, -CH ₂ -COOH or -OCH ₂ -COOH,
00	Ar ¹	denotes phenylene or piperazinediyl,

	Het	denotes a mono- or bicyclic saturated, unsaturated or
		aromatic heterocycle having 1 to 4 N, O and/or S atoms,
		which may be unsubstituted or mono-, di- or trisubsti-
_		tuted by Hal, A, NHA, NA₂, OA, COOA, CN,
5		-(CH ₂) _p -Ar, -(CH ₂) _t -OH, -(CH ₂) _p -Het ¹ or carbonyl oxygen
		(=O),
	Het ¹	denotes a mono- or bicyclic saturated, unsaturated or
		aromatic heterocycle having 1 to 4 N, O and/or S atoms,
10		which may be unsubstituted or mono- or disubstituted by
		A or carbonyl oxygen (=O),
	Het ²	denotes a monocyclic aromatic heterocycle having 1 to 3
		N, O and/or S atoms, which may be unsubstituted or
15		mono- or disubstituted by A,
	Het ³	denotes a monocyclic saturated or aromatic heterocycle
		having 1 to 3 N, O and/or S atoms, which may be unsub-
		stituted or mono- or disubstituted by A,
00	Het⁴	denotes a mono- or bicyclic saturated, unsaturated or
20		aromatic heterocycle having 1 to 4 N, O and/or S atoms,
		which may be unsubstituted or mono-, di- or trisubsti-
		tuted by Hal, A, CONH ₂ , CONHA, CONA ₂ or Ar ² ,
	Ar^2	denotes phenyl which is unsubstituted or mono-, di- or
25		trisubstituted by Hal, A, OH, OA, NH ₂ , NO ₂ , CN, COOH,
		COOA, CONH ₂ , NHCOA, NHCONH ₂ , NHSO ₂ A, CHO,
		COA, SO ₂ NH ₂ or SO ₂ A,
	R^7 , R^8 , R^9 , R^8	each, independently of one another, denote H, A or
30		$-(CH_2)_p$ -Ar,
	Α	denotes alkyl having 1 to 10 C atoms, where, in addition,
		1-7 H atoms may be replaced by F and/or chlorine,
	m	denotes 0, 1, 2, 3 or 4,
35	n	denotes 0 or 1,
33	р	denotes 0, 1, 2, 3 or 4,
	q	denotes 0, 1, 2, 3 or 4,

denotes 0, 1, 2, 3 or 4, r denotes 0, 1, 2, 3 or 4, S denotes F, Cl, Br or I, Hal and, if X = C, 5 R¹ and R² together may also denote -(CH₂)₄- or R² and R³ together may also denote -(CHR⁷-CHR⁸-NR⁹-CHR¹⁰)-, and, if Ar¹ denotes piperazinediyl, R⁶ may also denote H or alkyl hav-10 ing 1-6 C atoms, and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios. Compounds according to Claim 1 in which 2. 15 R^1 denotes A, OH, NH₂, -(CH₂)_m-Ar or -(CH₂)_m-Het², denotes phenyl which is unsubstituted or mono-, di- or Ar trisubstituted by Hal, A, OA, COOH or COOA, m denotes 0, 20 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios. Compounds according to Claim 1 or 2 in which 3. denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$, 25 R^4 denotes 0 or 1, s denotes 1, n Ar^1 denotes phenylene, R^6 denotes Het⁴, 30 Υ denotes O, Het⁴ denotes pyridyl which is unsubstituted or monosubstituted by CONHA, or benzo-1,2,5-thiadiazol-5-yl,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10

15

20

35

Compounds according to one or more of Claims 1-3 in which 4. denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶, R^4 denotes 1, s denotes 0, n denotes (CH₂)_a, Υ denotes 0, q denotes Het⁴, R^6 denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, Het⁴ 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar², denotes phenyl which is unsubstituted or mono-, di- or Ar^2

trisubstituted by A, and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 5. Compounds according to one or more of Claims 1-4 in which
- R^4 denotes - $(CH_2)_s$ - $(Ar^1)_n$ -Y- R^6 ,
 - s denotes 0,
 - n denotes 0,
 - Y denotes $(CH_2)_a$,
- 25 q denotes 0,
 - R^6 denotes -(CH₂)_r-NH₂, -(CH₂)_r-NHA or -(CH₂)_r-NA₂,
 - r denotes 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 6. Compounds according to one or more of Claims 1-5 in which
 - R^4 denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
 - s denotes 0,
 - n denotes 1,
 - Ar¹ denotes phenylene,

9.

		Υ	denotes O, (CH ₂) _q or NH,
		R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
		q	denotes 0, 1, 2, 3 or 4,
_		r	denotes 0, 1, 2, 3 or 4,
5		and pharma	aceutically usable derivatives, solvates, tautomers, salts
		and stereoi	somers thereof, including mixtures thereof in all ratios.
	7.	Compound	s according to one or more of Claims 1-6 in which
10		R⁴	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
		s	denotes 1, 2, 3 or 4,
		n	denotes 0,
		Υ	denotes (CH ₂) _q ,
15		q	denotes 0,
		R^6	denotes Het⁴,
		Het⁴	denotes a monocyclic saturated heterocycle having 1 to
			2 N and/or O atoms, which may be unsubstituted or
00			mono-or disubstituted by A,
20		and pharma	aceutically usable derivatives, solvates, tautomers, salts
		and stereoisomers thereof, including mixtures thereof in all rat	
	8.	Compound	s according to one or more of Claims 1-7 in which
25		R^1	denotes A, OH, NH_2 , - $(CH_2)_m$ -Ar,
		m	denotes 0,
		Ar	denotes phenyl which is unsubstituted or mono-, di- or
			trisubstituted by Hal, A, OA, COOH or COOA,
30		R^2	if X = N is absent or
			if X = C denotes CN,
		R^3	denotes H, A, -S-A, phenyl or -(CH ₂) _p -Het,
		and pharma	aceutically usable derivatives, solvates, tautomers, salts
35		and stereoi	somers thereof, including mixtures thereof in all ratios.

Compounds according to one or more of Claims 1-8 in which

 R^1 denotes A, OH, NH₂, -(CH₂)_m-Ar, denotes 0, m denotes phenyl which is unsubstituted or mono-, di- or Ar trisubstituted by Hal, A, OA, COOH or COOA, 5 R^2 if X = Nis absent or if X = Cdenotes CN, R^3 denotes H, A, -S-A, phenyl or -(CH₂)_p-Het, denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶, R^4 10 denotes 0, S denotes 0, n Υ denotes (CH₂)_a, denotes 0, q R^6 denotes $-(CH_2)_r$ -NH₂, $-(CH_2)_r$ -NHA or $-(CH_2)_r$ -NA₂, 15 denotes 1, 2, 3 or 4, and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios. 20 10. Compounds according to one or more of Claims 1-9 in which denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶, R^4 denotes 0, s denotes 1, n 25 Υ denotes (CH₂)_a, denotes 0, q R^6 denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$, denotes 0, r and pharmaceutically usable derivatives, solvates, tautomers, salts 30 and stereoisomers thereof, including mixtures thereof in all ratios. 11. Compounds according to one or more of Claims 1-10 in which denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶, R^4 35 s denotes 0,

denotes 0 or 1,

n

35

		Υ	denotes (CH ₂) _q ,
		q	denotes 0,
		R ⁶	denotes - $(CH_2)_r$ - NH_2 , - $(CH_2)_r$ - NHA or - $(CH_2)_r$ - NA_2 ,
_		r	denotes 0, 1, 2, 3 or 4,
5		and pharma	ceutically usable derivatives, solvates, tautomers, salts
		and stereois	omers thereof, including mixtures thereof in all ratios.
	12.	Compounds	according to one or more of Claims 1-11 in which
10		R ⁴	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
		s	denotes 0,
		n	denotes 0 or 1,
		Υ	denotes (CH ₂) _q ,
15		R^6	denotes $-(CH_2)_r$ -NH ₂ , $-(CH_2)_r$ -NHA or $-(CH_2)_r$ -NA ₂ ,
		Ar ¹	denotes phenylene,
		Υ	denotes O, $(CH_2)_q$ or NH,
•		q	denotes 0, 1, 2, 3 or 4,
		r	denotes 0, 1, 2, 3 or 4,

and stereoisomers thereof, including mixtures thereof in all ratios.

and pharmaceutically usable derivatives, solvates, tautomers, salts

13. Compounds according to one or more of Claims 1-12 in which

25 R^1 denotes A, OH, NH_2 , $-(CH_2)_m$ -Ar,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

30 R^2 if X = N is absent or if X = C denotes CN,

 R^3 denotes H, A, -S-A, phenyl or - $(CH_2)_p$ -Het,

 R^4 denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,

s denotes 0,

n denotes 0 or 1,

 $Y \qquad \qquad denotes \ (CH_2)_q,$

 R^6 denotes $-(CH_2)_r$ -NH₂, $-(CH_2)_r$ -NHA or $-(CH_2)_r$ -NA₂, Ar^1 denotes phenylene, Υ denotes O, (CH₂)_a or NH, denotes 0, 1, 2, 3 or 4, q 5 denotes 0, 1, 2, 3 or 4, r and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios. 10 14. Compounds according to one or more of Claims 1-13 in which R^1 denotes A, OH, NH₂, -(CH₂)_m-Ar, denotes 0, m denotes phenyl which is unsubstituted or mono-, di- or Ar trisubstituted by Hal, A, OA, COOH or COOA, 15 R^2 if X = Nis absent or if X = Cdenotes CN, R^3 denotes H, A, -S-A, phenyl or -(CH₂)_p-Het, denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶, R^4 20 denotes 0, s denotes 1, n Ar¹ denotes phenylene, R^6 denotes Het⁴, 25 Υ denotes O. Het⁴ denotes pyridyl which is unsubstituted or monosubstituted by CONHA, or benzo-1,2,5-thiadiazol-5-yl, and pharmaceutically usable derivatives, solvates, tautomers, salts 30 and stereoisomers thereof, including mixtures thereof in all ratios. 15. Compounds according to one or more of Claims 1-14 in which denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶, R^4 35 denotes 0 or 1, S denotes 0 or 1, n

30

35

denotes O or (CH₂)_q, Υ denotes 0, q R^6 denotes Het⁴. denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, Het⁴ 5 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar², denotes phenyl which is unsubstituted or mono-, di- or Ar^2 trisubstituted by A, Ar^1 10 denotes phenylene, and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

16. Compounds according to one or more of Claims 1-15 in which
Het denotes a monocyclic saturated or aromatic heterocycle
having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA,
NA₂, COOA, benzyl, -(CH₂)_t-OH or
-(CH₂)_p-Het¹,

Het¹ denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

17. Compounds according to one or more of Claims 1-16 in which

Het denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl,

pyridyl or furyl, which are unsubstituted or may be

mono-, di- or trisubstituted by Hal, A, NHA, NA₂, COOA,

benzyl, -(CH₂)_t-OH or -(CH₂)_p-Het¹,

Het¹ denotes morpholinyl, pyrrolidinyl, pyridyl

5

25

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10 18. Compounds according to one or more of Claims 1-17 in which $R^4 \qquad \text{denotes -}(CH_2)_s\text{-}(Ar^1)_n\text{-}Y\text{-}R^6,$ s denotes 0 or 1,

n denotes 0 or 1,

15 Y denotes O, (CH₂)_q or NH,

Ar¹ denotes phenylene,

q denotes 0, 1, 2, 3 or 4,

R⁶ denotes Het^4 , $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,

r denotes 0, 1, 2, 3 or 4,

Het⁴ denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole,

1,2,3-triazole, thienyl or furyl, each of which is unsubsti-

tuted or monosubstituted by CONHA, A and/or Ar²,

Ar² denotes phenyl which is unsubstituted or mono-, di- or

trisubstituted by A,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

19. Compounds according to one or more of Claims 1-18 in which

 R^1 denotes A, OH, NH_2 , $-(CH_2)_m$ -Ar,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or

trisubstituted by Hal, A, OA, COOH or COOA,

 R^2 if X = N is absent or

15

35

if X = Cdenotes CN,

 R^3 denotes H, A, -S-A, phenyl or -(CH₂)_p-Het,

denotes a monocyclic saturated or aromatic heterocycle Het having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA,

NA₂, COOA, benzyl, -(CH₂)_t-OH or

-(CH₂)_p-Het¹,

denotes an unsubstituted monocyclic saturated or aro-10 Het¹

matic heterocycle having 1 to 2 N and/or O atoms,

or

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

20	20.	Compound	Is according to one or more of Claims 1-19 in which
		R ⁴	denotes $-(CH2)s-(Ar1)n-Y-R6,$
		s	denotes 0, 1, 2, 3 or 4,
		n	denotes 0 or 1,
25		Υ	denotes O or (CH ₂) _q ,
		Ar ¹	denotes phenylene,
		q	denotes 0,
		R^6	denotes Het^4 , -(CH ₂) _C NH ₂ , -(CH ₂) _C NHA or -(CH ₂) _C

2)_r-NA₂,

denotes 0, 1, 2, 3 or 4, r 30

denotes a monocyclic saturated or aromatic heterocycle Het⁴ having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, CONH₂, CONHA, CONA₂ or Ar²,

 Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

25

30

35

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 21. Compounds according to one or more of Claims 1-20 in which

 Het⁴ denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine,
 thiazole or imidazole, each of which is unsubstituted or
 monosubstituted by CONHA, A and/or Ar²,
 and pharmaceutically usable derivatives, solvates, tautomers, salts
 and stereoisomers thereof, including mixtures thereof in all ratios.
- 22. Compounds according to one or more of Claims 1-21 in which

 R⁴ denotes 4-(pyridin-4-yloxy)phenyl, 4-(pyridin-4-yloxy)
 phenylmethyl or 4-(benzo-1,2,5-thiadiazol-5-yloxy)
 phenyl, where the pyridine radical may be substituted by

 CONHCH₃,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

23. Compounds according to one or more of Claims 1-22 in which

Het¹ denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,

or
$$\{-N, N, M\}$$

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

24. Compounds according to one or more of Claims 1-23 in which

Het¹ denotes morpholinyl, pyrrolidinyl, piperidinyl, pyridyl

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

25. Compounds according to one or more of Claims 1-24 in which
 Het² denotes an unsubstituted monocyclic aromatic heterocycle having 1-2 N, O and/or S atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

15

20

26. Compounds according to one or more of Claims 1-25 in which

 R^1 denotes A, OH, NH₂, -(CH₂)_m-Ar or -(CH₂)_m-Het²,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or

trisubstituted by Hal, A, OA, COOH or COOA,

 R^2 if X = N is absent or

if X = C

denotes H, CN, COOA or phenyl,

25

 R^3 denotes H, A, -S-A, phenyl, NH-benzyl, - $(CH_2)_p$ -Het, NH- $(CH_2)_p$ -Het, NA₂, NH-alkylene-NA₂ or

NA-alkylene-NA₂,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

30

27. Compounds according to one or more of Claims 1-26 in which

 R^2 if X = N is absent or

if X = C

35

denotes H, CN, (CH₂)_oAr", (CH₂)_oCOOA or SO₂A,

		Ar"	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,
		0	denotes 0 or 1,
5		•	ceutically usable derivatives, solvates, tautomers, salts omers thereof, including mixtures thereof in all ratios.
	28.	Compounds	according to one or more of Claims 1-27 in which
		R^1	denotes A, OH, NH_2 , - $(CH_2)_m$ -Ar' or - $(CH_2)_m$ -Het ² ,
10		Ar'	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,
		m	denotes 0,
15		Het ²	denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or pyridyl,
15		and pharma	ceutically usable derivatives, solvates, tautomers, salts
		•	omers thereof, including mixtures thereof in all ratios.
00	29.	Compounds	according to one or more of Claims 1-28 in which
20		X	denotes C or N,
		В	denotes N, CH or C-CN,
		R ¹	denotes A, OH, NH_2 , $-(CH_2)_m$ -Ar' or $-(CH_2)_m$ -Het ² ,
		Ar'	denotes phenyl which is unsubstituted or mono-, di- or
25			trisubstituted by Hal, OA, A or COOA,
		m	denotes 0,
		Het ²	denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or
			pyridyl,
30		R^2	if X = N is absent or
			if $X = C$
			denotes H, CN, (CH ₂) _o Ar", (CH ₂) _o COOA or SO ₂ A,
		Ar"	denotes phenyl which is unsubstituted or mono-, di- or
35			trisubstituted by Hal or OA,
		0	denotes 0 or 1,

	R^3	denotes H, A, -S-A, phenyl, NH-benzyl, -(CH ₂) _p -Het,
		NH-(CH ₂) _p -Het, NA ₂ , NH-alkylene-NA ₂ or
		NA-alkylene-NA ₂ ,
_	Het	denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl,
5	•	pyridyl or furyl, which are unsubstituted or may be
		mono-, di- or trisubstituted by Hal, A, NHA, NA ₂ , COOA,
		benzyl, $-(CH_2)_t$ -OH or $-(CH_2)_p$ -Het ¹ ,
	Het ¹	denotes morpholinyl, pyrrolidinyl, pyridyl
10		or $\{-N, N, M\}$
15	R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
13	Υ	denotes O or (CH ₂) _q ,
	R^5	denotes H or CH ₃ ,
20	R⁴ and R⁵	together also denote $\operatorname{Het^4-N} \subset \operatorname{CH_2-CH_2-} \subset CH_2-CH_$
	R^6	denotes Het^4 , -(CH ₂) _r -NH ₂ , -(CH ₂) _r -NHA or -(CH ₂) _r -NA ₂ ,
	Het⁴	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine,
		thiazole or imidazole, each of which is unsubstituted or
		monosubstituted by CONHA, A and/or Ar ² ,
25	Ar ¹	denotes phenylene or piperazinediyl,
	Ar ²	denotes phenyl which is unsubstituted or mono-, di- or
		trisubstituted by A,
	R ⁷ , R ⁸ , R ⁹ , R	each, independently of one another, denote H, A or
30		-(CH ₂) _p -Ar,
	Α	denotes alkyl having 1 to 10 C atoms, where, in addi-
•		tion, 1-7 H atoms may be replaced by F and/or chlorine,
	n	denotes 0 or 1,
35	р	denotes 0, 1, 2, 3 or 4,
	q	denotes 0, 1, 2, 3 or 4,
	•	

```
denotes 0, 1, 2, 3 or 4,
                ٢
                                  denotes 0, 1, 2, 3 or 4,
                 s
                                  denotes 1, 2, 3 or 4,
                t
                                  denotes F, Cl, Br or I,
                 Hal
5
                 and, if X = C,
                           R<sup>1</sup> and R<sup>2</sup>
                                                together may also denote -(CH<sub>2</sub>)<sub>4</sub>- or
                           R<sup>2</sup> and R<sup>3</sup> together may also denote -(CHR<sup>7</sup>-NR<sup>8</sup>-CHR<sup>9</sup>-
                           CHR<sup>10</sup>)-.
10
                and, if Ar<sup>1</sup> denotes piperazinediyl, R<sup>6</sup> may also denote H or alkyl hav-
                 ing 1-6 C atoms,
                 and pharmaceutically usable derivatives, solvates, tautomers, salts
                 and stereoisomers thereof, including mixtures thereof in all ratios.
15
          30. Compounds according to one or more of Claims 1-29 in which
                 Χ
                                  denotes C or N.
                                  denotes N, CH or C-CN,
                 В
20
                 R^1
                                  denotes A, OH, NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>m</sub>-Ar' or -(CH<sub>2</sub>)<sub>m</sub>-Het<sup>2</sup>,
                 Ar'
                                  denotes phenyl which is unsubstituted or mono-, di- or
                                  trisubstituted by Hal, OA, A or COOA,
                                  denotes 0,
                 m
25
                 Het<sup>2</sup>
                                  denotes an unsubstituted monocyclic aromatic hetero-
                                  cycle having 1-2 N, O and/or S atoms,
                 R^2
                                  if X = N
                                                is absent or
                                  if X = C
                                  denotes H, CN, (CH<sub>2</sub>)<sub>o</sub>Ar", (CH<sub>2</sub>)<sub>o</sub>COOA or SO<sub>2</sub>A,
30
                                  denotes phenyl which is unsubstituted or mono-, di- or
                 Ar"
                                  trisubstituted by Hal or OA,
                                  denotes 0 or 1.
                 R^3
                                  denotes H, A, -S-A, phenyl, NH-benzyl, -(CH<sub>2</sub>)<sub>p</sub>-Het,
35
                                  NH-(CH<sub>2</sub>)<sub>p</sub>-Het, NA<sub>2</sub>, NH-alkylene-NA<sub>2</sub> or
                                   NA-alkvlene-NA<sub>2</sub>.
```

5	Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA ₂ , COOA, benzyl, -(CH ₂) _t -OH or
•	Het ¹	-(CH ₂) _p -Het ¹ , denotes morpholinyl, pyrrolidinyl, pyridyl
10	Tiet	or {-NH
	R ⁴	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
	Υ	denotes O or (CH ₂) _q ,
15	R^5	denotes H or CH ₃ ,
, 0	R ⁴ and R ⁵	together also denote Het ⁴ – N CH ₂ -CH ₂ -,
	R^6	denotes Het^4 , -(CH_2) _r - NH_2 , -(CH_2) _r - NHA or -(CH_2) _r - NA_2 ,
20	Het⁴	denotes a monocyclic saturated or aromatic heterocycle
		having 1 to 3 N, O and/or S atoms, which may be unsub-
		stituted or mono-, di- or trisubstituted by A, CONH ₂ ,
		CONHA, CONA ₂ or Ar ² ,
25	Ar ¹	denotes phenylene or piperazinediyl,
20	Ar^2	denotes phenyl which is unsubstituted or mono-, di- or
		trisubstituted by A,
	R^7 , R^8 , R^9 , R^8	each, independently of one another, denote H, A or
		$-(CH_2)_p$ -Ar,
30	Ä	denotes alkyl having 1 to 10 C atoms, where, in addition,
		1-7 H atoms may be replaced by F and/or chlorine,
	n	denotes 0 or 1,
	p	denotes 0, 1, 2, 3 or 4,
35	q	denotes 0, 1, 2, 3 or 4,
	r	denotes 0, 1, 2, 3 or 4,

denotes 0, 1, 2, 3 or 4,
 denotes 1, 2, 3 or 4,
 denotes F, Cl, Br or I,

5 and, if X = C,

R¹ and R² together may also denote -(CH₂)₄- or R² and R³ together may also denote -(CHR⁷-NR⁸-CHR⁹-CHR¹⁰)-,

and, if Ar¹ denotes piperazinediyl, R⁶ may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

31. Compounds according to one or more of Claims 1-30 in which

X denotes N,

B denotes N, CH or C-CN,

 R^1 denotes NH_2 ,

R² is absent,

 R^3 denotes H, A, -S-A, phenyl, NH-benzyl, -(CH₂)_p-Het,

NH-(CH₂)_p-Het, NA₂, NH-alkylene-NA₂ or

NA-alkylene-NA₂,

Het denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl,

pyridyl or furyl, which are unsubstituted or may be

mono-, di- or trisubstituted by Hal, A, NHA, NA2, COOA,

benzyl, $-(CH_2)_t$ -OH or $-(CH_2)_p$ -Het¹,

Het denotes morpholinyl, pyrrolidinyl, pyridyl

35

15

20

 R^4 denotes - $(CH_2)_s$ - $(Ar^1)_n$ -Y- R^6 ,

		Υ	denotes O or (CH ₂) _q ,		
		R^5	denotes H or CH ₃ ,		
5		R ⁴ and R ⁵	together also denote $\operatorname{Het^4-N} \subset \operatorname{CH_2-CH_2-} \subset \operatorname{CH_2-CH_2-}$		
		R^6	denotes Het^4 , -(CH ₂) _r -NH ₂ , -(CH ₂) _r -NHA or -(CH ₂) _r -NA ₂ ,		
		Het⁴	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine,		
			thiazole or imidazole, each of which is unsubstituted or		
10			monosubstituted by CONHA, A and/or Ar ² ,		
10		Ar ¹	denotes phenylene or piperazinediyl,		
		Ar^2	denotes phenyl which is unsubstituted or mono-, di- or		
			trisubstituted by A,		
		Α	denotes alkyl having 1 to 10 C atoms, where, in addition,		
15			1-7 H atoms may be replaced by F and/or chlorine,		
		n	denotes 0 or 1,		
		p	denotes 0, 1, 2, 3 or 4,		
		q	denotes 0, 1, 2, 3 or 4,		
20		r	denotes 0, 1, 2, 3 or 4,		
		s	denotes 0, 1, 2, 3 or 4,		
		t	denotes 1, 2, 3 or 4,		
		Hal	denotes F, CI, Br or I,		
25		and, if Ar ¹ de	enotes piperazinediyl, R ⁶ may also denote H or alkyl hav-		
		ing 1-6 C atoms,			
		and pharma	ceutically usable derivatives, solvates, tautomers, salts		
		and stereois	omers thereof, including mixtures thereof in all ratios.		
30	32.	Compounds	according to one or more of Claims 1-31 in which		
	•	X	denotes N,		
		В	denotes N, CH or C-CN,		
		R ¹	denotes NH ₂ ,		
35		R^2	is absent,		

	R^3	denotes H, A, -S-A, phenyl, NH-benzyl, -(CH ₂) _p -Het,
		NH-(CH ₂) _p -Het, NA ₂ , NH-alkylene-NA ₂ or
		NA-alkylene-NA ₂ ,
	Het	denotes a monocyclic saturated or aromatic heterocycle
5		having 1 to 3 N and/or O atoms, which may be unsub-
		stituted or mono-, di- or trisubstituted by Hal, A, NHA,
		NA ₂ , COOA, benzyl, -(CH ₂) _t -OH or
		-(CH ₂) _p -Het ¹ ,
10	Het ¹	denotes morpholinyl, pyrrolidinyl, pyridyl
15		or $\{-N, N, N\}$
13	R ⁴	denotes $-(CH2)s-(Ar1)n-Y-R6,$
	Y	denotes O or (CH ₂) _q ,
	R^5	denotes H or CH ₃ ,
20	R⁴ and R⁵	together also denote $\operatorname{Het^4-N} \subset \operatorname{CH_2-CH_2-} \subset CH_2-CH_$
	R^6	denotes Het^4 , - $(\text{CH}_2)_r$ - NH_2 , - $(\text{CH}_2)_r$ - NHA or - $(\text{CH}_2)_r$ - NA_2 ,
	Het⁴	denotes a monocyclic saturated or aromatic heterocycle
0.5		having 1 to 3 N, O and/or S atoms, which may be unsub-
25		stituted or mono-, di- or trisubstituted by A, CONH ₂ ,
		CONHA, CONA ₂ or Ar ² ,
	Ar ¹	denotes phenylene or piperazinediyl,
	Ar^2	denotes phenyl which is unsubstituted or mono-, di- or
30		trisubstituted by A,
	Α	denotes alkyl having 1 to 10 C atoms, where, in addition,
		1-7 H atoms may be replaced by F and/or chlorine,
	n	denotes 0 or 1,
35	р	denotes 0, 1, 2, 3 or 4,
	q	denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

t denotes 1, 2, 3 or 4,

Hal denotes F, Cl, Br or l,

and, if Ar¹ denotes piperazinediyl, R⁶ may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

33. Compounds according to Claim 1, selected from the group

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,

5

10

15

25

30

10

5

(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

20

(7-methyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methyl-aminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

25

(5,7-bistrifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

30

(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

35

(2-phenylthiazol-4-ylmethyl)-(7-phenyl-5-trifluoromethyl-1,2,4-tri-azolo[1,5-a]pyrimidin-2-yl)amine,

(2-phenylthiazol-4-ylmethyl)-(7-methyl-5-trifluoromethyl-1,2,4-tri-azolo[1,5-a]pyrimidin-2-yl)amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)benzyl]amine,

(3-dimethylaminopropyl)-(7-methyl-5-trifluoromethyl-1,2,4-tria-zolo[1,5-a]pyrimidin-2-yl)amine,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazool[1,5-a]pyrimidine-3-carbonitrile,

7-methyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,

5,7-dimethyl-2-[4-(pyridin-4-yloxy)phenylamino]pyrazolo[1,5-a]-pyrimidine-3-carbonitrile,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylmethylamino]-5-trifluoro-methylpyrazolo[1,5-a]pyrimidine-3-carbonitrile,

15

10

5

20

6-benzyl-2-[3-(4-methylpiperazin-1-yl)propylamino]-5,6,7,8-tetrahydro-1,3,3a,6,9-pentaazacyclopenta[b]naphthalen-4-ol,

ΗÓ

35

25

-CI

5 N=

20

15

25

10

15

20

25

30

NH₂ NH₂

15

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 34. Process for the preparation of compounds of the formula I according to Claims 1-33 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, characterised in that
 - a) for the preparation of compounds of the formula I in which X denotes C, a compound of the formula II

in which R⁴, R⁵ and B have the meanings indicated in Claim 1,

i) is reacted with a compound of the formula IIIa

in which R¹ OA and

R² and R³ have the meanings indicated in Claim 1,

or

ii) with a compound of the formula IIIb

5

$$R^1$$
 R^2
 R^3

10

in which R^1 , R^2 and R^3 have the meanings indicated in Claim 1, and A denotes alkyl having 1, 2, 3 or 4 C atoms,

15

or

iii) with a compound of the formula IIIc

20

$$\begin{array}{c|c}
R^1 \\
R^2 \\
R^3
\end{array}$$
IIIc

25

in which

30

R¹, besides the meanings indicated in Claim 1, also denotes OA, R² and R³ have the meanings indicated in Claim 1, and A, A' each, independently of one another, denote alkyl having 1, 2, 3 or 4 C atoms,

35

or A and A' together may also form a butylene or pentylene chain,

or

b) for the preparation of compounds of the formula I in which X denotes N and R¹ denotes NH₂, a compound of the formula II is reacted with a compound of the formula IIId

10

5

in which R³ has the meaning indicated in Claim 1, and A denotes alkyl having 1, 2, 3 or 4 C atoms,

or

20

- c) for the preparation of compounds of the formula I in which
- X denotes N,
- R^1 denotes H, A, -(CH₂)_m-Ar or -(CH₂)_m-Het²,
- R³ denotes -S-A

a compound of the formula II is reacted with a compound of the formula IIIe

30

$$R^1$$
 N
 $A-S$
 S
 A

in which

35

 R^1 denotes H, A, $-(CH_2)_m$ -Ar or $-(CH_2)_m$ -Het² and A denotes alkyl having 1, 2, 3 or 4 C atoms,

and/or that one or more radical(s) R¹,R² and/or R³ in a compound of the formula I is (are) converted into one or more radical(s) R¹,R² and/or R³,

5

by, for example,

- i) converting an alkylsulfanyl group into an amine,
- ii) hydrolysing an ester to the acid, reducing it to the aldehyde or alcohol,
- iii) reducing a nitrile to the aldehyde or amine,

and/or

a base or acid of the formula I is converted into one of its salts.

15

20

- 35. Medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
- 25
- 36. Use of compounds according to Claim 1 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.
- 30
- 37. Use according to Claim 36, where the kinases are selected from the group of the tyrosine kinases.
- 38. Use according to Claim 37, where the tyrosine kinases are TIE-2,
 VEGFR, PDGFR, FGFR and/or FLT/KDR.

- 39. Use according to Claim 37 of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates, tautomers and stereo-isomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of tyrosine kinases by the compounds according to Claim 1.
- Use according to Claim 39 for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR by the compounds according to Claim 1.
- 15 41. Use according to Claim 39 or 40, where the disease to be treated is a solid tumour.
- 42. Use according to Claim 41, where the solid tumour originates from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and/or the lung.
- 43. Use according to Claim 41, where the solid tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.
- 30 44. Use according to Claim 41, where the solid tumour originates from the group of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.
- 45. Use according to Claim 39 or 40, where the disease to be treated is a tumour of the blood and immune system.

- 46. Use according to Claim 45, where the tumour originates from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.
- 5
 47. Use according to Claim 39 or 40 for the treatment of a disease in which angiogenesis is implicated.
 - 48. Use according to Claim 47, where the disease is an ocular disease.
 - 49. Use according to Claim 39 or 40 for the treatment of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and/or inflammatory diseases.
 - 50. Use according to Claim 49, where the inflammatory disease originates from the group rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.
- 51. Use according to Claim 39 or 40 for the treatment of bone pathologies, where the bone pathology originates from the group osteosarcoma, osteoarthritis and rickets.
- 52. Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

- 53. Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.
- 54. Use according to Claim 39 or 40 for the preparation of a medicament for the treatment of diseases which are based on disturbed TIE-2 activity,

 where a therapeutically effective amount of a compound according to Claim 1 is administered in combination with a growth-factor receptor inhibitor.

55. Intermediate compounds of the formula I-1

in which

5

10

20

30

B denotes N, CH or C-CN, R^4 denotes - $(CH_2)_s$ - $(Ar^1)_n$ -Y- R^6 , R^5 denotes H or CH_3 ,

$${
m R}^4$$
 and ${
m R}^5$ together also denote ${
m Het}^4-{
m N}$ ${
m CH_2-CH_2-\atop CH_2-CH_2-}$

35 R^6 denotes Het^4 , -(CH₂)_r-NH₂, -(CH₂)_r-NHA or -(CH₂)_r-NA₂,

		Y Ar ¹	denotes O, S, (CH ₂) _q or NH, denotes phenylene or piperazinediyl,	
5		Het⁴	denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, CONH ₂ , CONHA, CONA ₂ or Ar ² ,	
		Ar ²	denotes phenyl which is unsubstituted or mono-, di- or	
10			trisubstituted by Hal, A, OH, OA, NH ₂ , NO ₂ , CN, COOH, COOA, CONH ₂ , NHCOA, NHCONH ₂ , NHSO ₂ A, CHO, COA, SO ₂ NH ₂ or SO ₂ A,	
		Α	denotes alkyl having 1 to 10 C atoms, where, in addition,	
			1-7 H atoms may be replaced by F and/or chlorine,	
15		n	denotes 0 or 1,	
		q	denotes 0, 1, 2, 3 or 4,	
		r	denotes 0, 1, 2, 3 or 4,	
		S	denotes 0, 1, 2, 3 or 4,	
20		Hal	denotes F, Cl, Br or I,	
20		and, if Ar ¹ denotes piperazinediyl, R ⁶ may also denote H or alkyl hav-		
		ing 1-6 C ato	oms,	
		and solvates	s, salts, tautomers and stereoisomers thereof, including	
		mixtures the	reof in all ratios.	
25				
	56.	. Intermediate compounds according to Claim 55		
		in which		
		В	denotes N, CH or C-CN,	
30		R ⁴	denotes $-(CH_2)_s$ - $(Ar^1)_n$ -Y- R^6 ,	
		Υ	denotes O or (CH ₂) _q ,	
		R ⁵	denotes H or CH ₃ ,	
35		R ⁴ and R ⁵	together also denote Het ⁴ – N CH ₂ -CH ₂ - CH ₂ -CH ₂ -	
		R ⁶	denotes Het^4 , -(CH ₂) _r -NH ₂ , -(CH ₂) _r -NHA or -(CH ₂) _r -NA ₂ ,	

			•
		Het⁴	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine,
			thiazole or imidazole, each of which is unsubstituted or
			monosubstituted by CONHA, A and/or Ar ² ,
5		Ar ¹	denotes phenylene or piperazinediyl,
		Ar ²	denotes phenyl which is unsubstituted or mono-, di- or
			trisubstituted by A,
		Α	denotes alkyl having 1 to 10 C atoms, where, in addition,
			1-7 H atoms may be replaced by F and/or chlorine,
10		n	denotes 0 or 1,
		q	denotes 0, 1, 2, 3 or 4,
		r	denotes 0, 1, 2, 3 or 4,
		s	denotes 0, 1, 2, 3 or 4,
15		Hal	denotes F, Cl, Br or I,
		and, if Ar ¹ d	enotes piperazinediyl, R ⁶ may also denote H or alkyl hav-
		ing 1-6 C at	oms,
		and solvates	s, salts, tautomers and stereoisomers thereof, including
00		mixtures the	reof in all ratios.
20			
	57.	Intermediate	e compounds according to Claim 55 or 56, selected from
		the group	
•		<i>N</i> -[4-(p	yridin-4-yloxy)phenyl]-4 <i>H</i> -1,2,4-triazole-3,5-diamine,
25		N-{4-[2	-(N-methylaminocarbonyl)pyridin-4-yloxy]phenyl}-4 <i>H</i> -
		1,2,4-triazol	e-3,5-diamine,
		N-{3-[2	-(N-methylaminocarbonyl)pyridin-4-yloxy]phenyl}-4 <i>H</i> -
		1,2,4-triazolo	e-3,5-diamine,
30		<i>N</i> -[4-(p	yridin-4-yloxy)phenylmethyl]-4 <i>H</i> -1,2,4-triazole-3,5-di-
		amine,	
		<i>N</i> -(5-m	ethyl-2-phenyl-2 <i>H</i> -1,2,3-triazol-4-ylmethyl)-4 <i>H</i> -1,2,4-tri-
		azole-3,5-dia	amine,
		<i>N</i> -(2-pł	nenylthiazol-4-ylmethyl)-4 <i>H</i> -1,2,4-triazole-3,5-diamine,
35			

	N-[4-(2-diethylaminoethoxy)phenyl]-4H-1,2,4-triazole-3,5-di-
•	amine,
	N-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]-4H-1,2,4-triazole-
5	3,5-diamine,
0	N-[4-(pyridin-4-ylsulfanyl)phenyl]-4H-1,2,4-triazole-3,5-diamine,
	5-amino-3-[4-(pyridin-4-yloxy)phenylamino]-1 <i>H</i> -pyrazole-4-car-
	bonitrile,
40	N*3*-[4-(pyridin-4-yloxy)phenyl]-1H-pyrazole-3,5-diamine,
10	
	and solvates, salts, tautomers and stereoisomers thereof, including
	mixtures thereof in all ratios.
4-	
15	
20	
20	
25	
25	
30	
30	